Literature DB >> 29360393

Disproportionate Right Ventricular Dysfunction and Poor Survival in Group 3 Pulmonary Hypertension.

Kurt W Prins1, Lauren Rose1, Stephen L Archer2, Marc Pritzker1, E Kenneth Weir1, Felipe Kazmirczak1, Jeffrey R Misialek1, Thenappan Thenappan1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29360393      PMCID： PMC6005552          DOI： 10.1164/rccm.201712-2405LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  8 in total

1.  Gaining insights into pulmonary hypertension in respiratory diseases.

Authors:  Joan Albert Barberà; Isabel Blanco
Journal:  Eur Respir J       Date:  2015-11       Impact factor: 16.671

2.  Pulmonary pulse wave transit time is associated with right ventricular-pulmonary artery coupling in pulmonary arterial hypertension.

Authors:  Kurt W Prins; E Kenneth Weir; Stephen L Archer; Jeremy Markowitz; Lauren Rose; Marc Pritzker; Richard Madlon-Kay; Thenappan Thenappan
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

Review 3.  Pulmonary hypertension in chronic lung diseases.

Authors:  Werner Seeger; Yochai Adir; Joan Albert Barberà; Hunter Champion; John Gerard Coghlan; Vincent Cottin; Teresa De Marco; Nazzareno Galiè; Stefano Ghio; Simon Gibbs; Fernando J Martinez; Marc J Semigran; Gerald Simonneau; Athol U Wells; Jean-Luc Vachiéry
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

Review 4.  Updated clinical classification of pulmonary hypertension.

Authors:  Gerald Simonneau; Michael A Gatzoulis; Ian Adatia; David Celermajer; Chris Denton; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; R Krishna Kumar; Michael Landzberg; Roberto F Machado; Horst Olschewski; Ivan M Robbins; Rogiero Souza
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

5.  Sex and race differences in right ventricular structure and function: the multi-ethnic study of atherosclerosis-right ventricle study.

Authors:  Steven M Kawut; João A C Lima; R Graham Barr; Harjit Chahal; Aditya Jain; Harikrishna Tandri; Amy Praestgaard; Emilia Bagiella; Jorge R Kizer; W Craig Johnson; Richard A Kronmal; David A Bluemke
Journal:  Circulation       Date:  2011-06-07       Impact factor: 29.690

6.  Right ventricular dysfunction and remodeling in chronic obstructive pulmonary disease without pulmonary hypertension.

Authors:  Janne Mykland Hilde; Ingunn Skjørten; Ole Jørgen Grøtta; Viggo Hansteen; Morten Nissen Melsom; Jonny Hisdal; Sjur Humerfelt; Kjetil Steine
Journal:  J Am Coll Cardiol       Date:  2013-07-10       Impact factor: 24.094

7.  Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort.

Authors:  Geoff Strange; David Playford; Simon Stewart; Jenny A Deague; Helen Nelson; Aaron Kent; Eli Gabbay
Journal:  Heart       Date:  2012-07-03       Impact factor: 5.994

8.  Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis.

Authors:  Kurt W Prins; Sue Duval; Jeremy Markowitz; Marc Pritzker; Thenappan Thenappan
Journal:  Pulm Circ       Date:  2017-03-24       Impact factor: 3.017
  8 in total
  10 in total

1.  Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide.

Authors:  Lauren Rose; Kurt W Prins; Stephen L Archer; Marc Pritzker; E Kenneth Weir; Jeffrey R Misialek; Thenappan Thenappan
Journal:  J Heart Lung Transplant       Date:  2018-09-14       Impact factor: 10.247

2.  Pulmonary hypertension in patients with interstitial pneumonia with autoimmune features.

Authors:  Bashar N Alzghoul; Robert Hamburger; Thomas Lewandowski; Brandon Janssen; Daniel Grey; Wei Xue; Ali Ataya; Hassan Alnuaimat; Diana C Gomez-Manjarres; Divya Patel; Raju Reddy
Journal:  Pulm Circ       Date:  2020-12-07       Impact factor: 3.017

3.  Mortality in US veterans with pulmonary hypertension: a retrospective analysis of survival by subtype and baseline factors.

Authors:  Aaron W Trammell; Amit J Shah; Lawrence S Phillips; C Michael Hart
Journal:  Pulm Circ       Date:  2019 Jan-Mar       Impact factor: 3.017

4.  Identification of novel metabolic signatures potentially involved in the pathogenesis of COPD associated pulmonary hypertension.

Authors:  Priyanka Choudhury; Anindita Bhattacharya; Sanjukta Dasgupta; Nilanjana Ghosh; Sayoni Senpupta; Mamata Joshi; Parthasarathi Bhattacharyya; Koel Chaudhury
Journal:  Metabolomics       Date:  2021-10-01       Impact factor: 4.290

Review 5.  Group 3 Pulmonary Hypertension: From Bench to Bedside.

Authors:  Navneet Singh; Peter Dorfmüller; Oksana A Shlobin; Corey E Ventetuolo
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

6.  Echocardiographic characteristics of patients with antisynthetase syndrome.

Authors:  Jaimie L Bryan; Ralph Matar; Abheek Raviprasad; Veronica Kuteyeva; Eduardo Milla; Omkar Begateri; Divya Patel; Diana G Manjarres; Saminder S Kalra; Jeffrey Robinson; Akram Khan; Raju Reddy
Journal:  Pulm Circ       Date:  2022-04-27       Impact factor: 2.886

7.  Predictive Value of Novel Inflammation-Based Biomarkers for Pulmonary Hypertension in the Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Authors:  Huanhuan Zuo; Xiaochen Xie; Jiahuan Peng; Lixin Wang; Rong Zhu
Journal:  Anal Cell Pathol (Amst)       Date:  2019-10-14       Impact factor: 2.916

Review 8.  Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension.

Authors:  Sasha Z Prisco; Thenappan Thenappan; Kurt W Prins
Journal:  JACC Basic Transl Sci       Date:  2020-12-28

9.  Clinical Determinants and Prognostic Implications of Right Ventricular Dysfunction in Pulmonary Hypertension Caused by Chronic Lung Disease.

Authors:  Kurt W Prins; Lauren Rose; Stephen L Archer; Marc Pritzker; E Kenneth Weir; Matthew D Olson; Thenappan Thenappan
Journal:  J Am Heart Assoc       Date:  2019-01-22       Impact factor: 5.501

10.  Diagnostic and prognostic significance of serum angiopoietin-1 and -2 concentrations in patients with pulmonary hypertension.

Authors:  Noriyuki Enomoto; Seiichiro Suzuki; Hironao Hozumi; Masato Karayama; Yuzo Suzuki; Kazuki Furuhashi; Tomoyuki Fujisawa; Yutaro Nakamura; Keiichi Odagiri; Takamichi Ishikawa; Kensuke Kataoka; Yasuhiro Kondoh; Masato Maekawa; Naoki Inui; Hiroshi Watanabe; Takafumi Suda
Journal:  Sci Rep       Date:  2021-07-29       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.